Pfizer's Quest to Stay Ahead of the Pack
Pfizer’s Quest to Stay Ahead of the Pack
The drugmaker has been a stable holding in unstable times. Now, though, it faces big challenges from rivals to its Lipitor and Viagra
Pfizer’s Quest to Stay Ahead of the Pack
The drugmaker has been a stable holding in unstable times. Now, though, it faces big challenges from rivals to its Lipitor and Viagra
Can Your Genomics Work Contribute to Biodefense
Three years ago, Luis Villarreal, a virologist at the University of California, Irvine, came up with the idea of using in vitro gene activation by PCR to study the proteome of a virus in hopes of developing a high-throughput platform for identifying new vaccines.
Villarreal and his collaborators at the university saw infectious disease as their primary target, but after the anthrax attacks in late 2001 they realized that their work might just as easily apply to tackling bioterror agents…
Biogen/Idec: still a matter of size
The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.
The State of Biotechnology
Researchers, government officials and industry executives will gather this weekend in Washington for the Biotechnology Industry Organization’s annual convention. Topics to be addressed at BIO 2003 range from science and regulatory affairs to bioethics and homeland security.
Coffee Plants Can Produce Less Caffeine
Researchers say they have genetically engineered coffee plants that have 70 percent less caffeine than usual in their leaves. The crucial question for brewing coffee � whether beans from those plants will have less caffeine � won’t be known for three to four years when the plants mature
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Recent Comments